| Azacitidine and venetoclax in previously untreated acute myeloid leukemia CD DiNardo, BA Jonas, V Pullarkat, MJ Thirman, JS Garcia, AH Wei, ... New England journal of medicine 383 (7), 617-629, 2020 | 2286 | 2020 |
| Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia CD DiNardo, K Pratz, V Pullarkat, BA Jonas, M Arellano, PS Becker, ... Blood, The Journal of the American Society of Hematology 133 (1), 7-17, 2019 | 1843 | 2019 |
| Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label … CD DiNardo, KW Pratz, A Letai, BA Jonas, AH Wei, M Thirman, ... The lancet oncology 19 (2), 216-228, 2018 | 762 | 2018 |
| Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial JE Cortes, S Khaled, G Martinelli, AE Perl, S Ganguly, N Russell, ... The Lancet Oncology 20 (7), 984-997, 2019 | 496 | 2019 |
| How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia BA Jonas, DA Pollyea Leukemia 33 (12), 2795-2804, 2019 | 184 | 2019 |
| Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: long term follow‐up from a phase 1b study DA Pollyea, K Pratz, A Letai, BA Jonas, AH Wei, V Pullarkat, M Konopleva, ... American journal of hematology 96 (2), 208-217, 2021 | 147 | 2021 |
| Measurable residual disease response and prognosis in treatment-naïve acute myeloid leukemia with venetoclax and azacitidine KW Pratz, BA Jonas, V Pullarkat, C Recher, AC Schuh, MJ Thirman, ... Journal of Clinical Oncology 40 (8), 855-865, 2022 | 135 | 2022 |
| SMRT and N-CoR corepressors are regulated by distinct kinase signaling pathways BA Jonas, ML Privalsky Journal of Biological Chemistry 279 (52), 54676-54686, 2004 | 111 | 2004 |
| NCCN Guidelines® insights: myelodysplastic syndromes, version 3.2022: featured updates to the NCCN guidelines PL Greenberg, RM Stone, A Al-Kali, JM Bennett, U Borate, AM Brunner, ... Journal of the National Comprehensive Cancer Network 20 (2), 106-117, 2022 | 105 | 2022 |
| Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine DA Pollyea, KW Pratz, AH Wei, V Pullarkat, BA Jonas, C Recher, S Babu, ... Clinical Cancer Research 28 (24), 5272-5279, 2022 | 102 | 2022 |
| Acute myeloid leukemia, version 3.2023, NCCN clinical practice guidelines in oncology DA Pollyea, JK Altman, R Assi, D Bixby, AT Fathi, JM Foran, I Gojo, ... Journal of the National Comprehensive Cancer Network 21 (5), 503-513, 2023 | 100 | 2023 |
| Optimizing survival outcomes with post‐remission therapy in acute myeloid leukemia BC Medeiros, SM Chan, NG Daver, BA Jonas, DA Pollyea American journal of hematology 94 (7), 803-811, 2019 | 99 | 2019 |
| Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial JM Watts, MR Baer, J Yang, T Prebet, S Lee, GJ Schiller, SN Dinner, ... The Lancet Haematology 10 (1), e46-e58, 2023 | 98 | 2023 |
| Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML S de Botton, P Fenaux, K Yee, C Récher, AH Wei, P Montesinos, ... Blood advances 7 (13), 3117-3127, 2023 | 87 | 2023 |
| Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia DJ DeAngelo, BA Jonas, JL Liesveld, DL Bixby, AS Advani, P Marlton, ... Blood, The Journal of the American Society of Hematology 139 (8), 1135-1146, 2022 | 86 | 2022 |
| Corepressors: custom tailoring and alterations while you wait M Goodson, BA Jonas, MA Privalsky Nuclear receptor signaling 3 (1), nrs. 03003, 2005 | 83 | 2005 |
| Long‐term follow‐up of VIALE‐A: venetoclax and azacitidine in chemotherapy‐ineligible untreated acute myeloid leukemia KW Pratz, BA Jonas, V Pullarkat, MJ Thirman, JS Garcia, H Döhner, ... American journal of hematology 99 (4), 615-624, 2024 | 80 | 2024 |
| ELN risk stratification is not predictive of outcomes for treatment-naïve patients with acute myeloid leukemia treated with venetoclax and azacitidine H Döhner, KW Pratz, CD DiNardo, BA Jonas, VA Pullarkat, MJ Thirman, ... Blood 140 (Supplement 1), 1441-1444, 2022 | 79 | 2022 |
| Alternative mRNA splicing of SMRT creates functional diversity by generating corepressor isoforms with different affinities for different nuclear receptors ML Goodson, BA Jonas, ML Privalsky Journal of Biological Chemistry 280 (9), 7493-7503, 2005 | 77 | 2005 |
| MDS prognostic scoring systems–past, present, and future BA Jonas, PL Greenberg Best Practice & Research Clinical Haematology 28 (1), 3-13, 2015 | 76 | 2015 |
Aaron S RosenbergUniversity of California, Davis School of MedicineVerificeret mail på ucdavis.edu
